William Blair Initiates RxSight Coverage with 'Market Perform' Amid Sales Growth Concerns

William Blair has initiated coverage of RxSight, Inc. (RXST) with a "Market Perform" rating. This cautious outlook stems from expectations of stalled sales growth in 2025, following a period of strong early adoption for the medical device company. Analysts are awaiting evidence of sustained commercial reacceleration before considering a more positive stance. RxSight recently narrowed its full-year revenue guidance and is strategically focusing on international expansion to drive future growth. The "Market Perform" rating suggests potential sideways movement or slight pressure on the stock until clearer signs of renewed momentum emerge.